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Summary Neuropeptide Y in the hypothalamus is a 
potent physiological stimulator of feeding, and may 
contribute to the characteristic metabolic defects of 
obesity when hypothalamic levels remain chronically 
elevated. Since corticosterone and insulin are impor- 
tantJJregulators of fuel metabolism, the longitudinal 
effects of chronic (6 days) intracerebroventricular in- 
fusion of neuropeptide Y in normal rats on the hypo- 
thalamo-pituitary-adrenal axis and on insulin secre- 
tion were studied. Neuropeptide Y-infused rats were 
either allowed to eat ad libitum, o r  were pair-fed 
with normophagic control rats. Neuropeptide Y in- 
creased the  basal plasma concentrations of adreno- 
corticotropic hormone and corticosterone during the 
first 2 days of its intracerebroventricular infusion 
and increased cold stress-induced plasma adrenocor- 
ticotropic hormone concentrations. After 4-6 days of 
central neuropeptide Y infusion, however, basal plas- 
ma adrenocorticotropic hormone and corticosterone 
concentrations were no different from control values 
(except in ad libitum-fed rats in which corticosteron- 
aemia remained elevated), they were unaffected by 
the stress of cold exposure, and the hypothalamic 
content of corticotropin-releasing factor immuno- 
reactivity was significantly decreased. A state of hy- 
perinsulinaemia was present throughout the 6 days 
of intracerebroventricular neuropeptide Y infusion, 
being more marked in the ad libitum-fed than in the 
pair-fed group. The proportions of insulin, proinsulin, 
and conversion intermediates in plasma and pancreas 
were unchanged. Hyperinsulinaemia of the pair-fed 
neuropeptide Y-infused rats was accompanied by 
muscle insulin resistance and white adipose tissue in- 
sulin hyperresponsiveness, as assessed by the in vivo 
uptake of 2-deoxyglucose. Finally, bilateral subdia- 
phragmatic vagotomy prevented both the basal and 
the marked glucose-induced hyperinsulinaemia of 
animals chronically infused with neuropeptide Y, de- 
monstrating that central neuropeptide Y-induced hy- 
perinsulinaemia is mediated by the parasympathetic 
nervous system. [Diabetologia (1997) 40: 1269-1277] 
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Neuropeptide Y (NPY) is a 36 amino acid peptide of 
the peripheral and central nervous system [1]. Cen- 
trally it is found in particularly high concentrations 
in the hypothalamus [1], where it is involved in the 
regulation of many neuroendocrine and autonomic 
functions [2, 3]. NPY is particularly well known for 
its role as a potent, physiological stimulator of feed- 
ing acting within discrete hypothalamic sites [4]. 
Defects in the activity of NPY-ergic neurones in 
the hypothalamus may contribute to the develop- 
ment of obesity, at least in rodents [5]. In support of 
this hypothesis, elevated levels of NPY and/or its 
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transcript  have  been  observed  in the hypotha lami  of  
genetical ly obese  rodents  such as fa/fa and cp/cp rats 
[6, 7] as well as ob/ob and db/db mice [8]. This in- 
crease has be e n  de tec t ed  ear ly  a f te r  weaning in faJfa 
rats, co r responding  with the t ime when  their  obesi ty  
syndrome  first becomes  appa ren t  [6]. Fu r the rmo re ,  
chronic  adminis t ra t ion  of  exogenous  N P Y  to specific 
hypo tha lamic  nuclei  or into the cerebra l  ventr icles  of  
normal  rats results  in many  of  the  defects  of  obesity, 
including a m a r k e d  increase in food  intake,  acceler- 
a ted body  weight  gain, hype rco r t i cos t e ronaemia  and 
hyper insul inaemia ,  leading to muscle  insulin resis- 
tance with respec t  to glucose uptake ,  and increased 
tr iglyceride s torage due to increased  insulin respon-  
siveness in whi te  adipose tissue [9-16]. 
It is of  no te  that  hype rco r t i cos t e ronaemia  and hy- 
per insu l inaemia  are c o m m o n  fea tures  of  many  states 
of obesi ty  associated with insulin resis tance in ro- 
dents  and in m a n  [17-20], and these h o r m o n a l  pertur-  
bations are o f  key  impor tance  in the NPY-induced  
obesi ty  syndrome.  Al though  prev ious  studies have in- 
vest igated the effects  of  N P Y  on the  hypotha lamo-p i -  
tu i ta ry-adrenal  (HPA)  axis and on  insulin secre t ion 
af ter  acute  in ject ion [3, 21], little is known  about  the 
ho r m ona l  effects  of  chronic  centra l  N P Y  administra-  
tion. Such knowledge  would con t r ibu te  to the under-  
s tanding of  the aet iology of  obesity, consider ing the 
chronical ly  e leva ted  hypo tha lamic  N P Y  levels associ- 
a ted with this pa tho logy  [6-8]. 
This work  the re fo re  a imed to charac ter i se  the t ime 
course of  changes  in secre t ion of  cor t i cos te rone  and 
insulin dur ing 6 days of  in t race rebroven t r i cu la r  
(i. c.v.) N P Y  infusion in normal  rats, as well as the 
routes  by which these two h o r m o n e s  are af fec ted  by 
centra l  NPY. 
GmbH, Wehrheim, Germany). An i. m. injection of amoxicillin 
(50 mg/kg; Smith Kline Beecham, Th6rishaus, Switzerland) 
was given, and animals were left for 7-10 days to recover 
from surgery, during which time they were handled daily and 
habituated to the blood-sampling procedure by thrice weekly 
rinsing of the jugular catheter with isotonic saline containing 
25 IU/ml heparin and 20 000 IU/ml penicillin. 
I. c. v. infusion of neuropeptide Y (NPY). Porcine NPY (15 ~g/ 
day; Bachem, Bubendorf, Switzerland) or its vehicle for con- 
trol rats (0.04 mol/1 phosphate-buffered saline, pH 7.4, with 
0.2 % bovine serum albumin (BSA) and 0.01% ascorbic acid) 
was i. c. v. infused for 6 days via a subcutaneously placed osmo- 
tic minipump (model 2001; Alza Corporation, Palo Alto, Ca- 
lif., USA) as detailed elsewhere [22]. One group of NPY-in- 
fused rats and their controls were allowed to eat ad libitum. A 
second group of NPY-infused animals was pair-fed to the 
amount of food consumed by the vehicle-infused control rats 
in order to prevent NPY-induced hyperphagia. In this group, 
pellets were distributed at 07.45, 12.00, 17.30 and 23.30 hours 
(6, 19, 37.5 and 37.5 % of the daily food allowance of 22.0 g, re- 
spectively). During i. c. v. infusion, food intake and body weight 
were measured daily, and a blood sample was collected from 
the jugular catheter into EDTA-coated tubes between 09.00 
and 10.00 hours each day, 1-2 h after removal of food from 
cages. Food was replaced after blood sampling (ad libitum-fed 
rats), or at 12.00 hours (pair-fed rats). Plasma was stored at - 
20~ until measurement of basal hormone and metabolite 
concentrations. 
Adrenocorticotropic hormone (A CTH) and corticosterone se- 
cretion induced by cold stress. An additional group of ad libi- 
turn-fed NPY-infused rats and their controls were exposed for 
2 h to a temperature of 5 ~ between 10.30 and 12.30 hours on 
the second day after the start of i. c.v. infusion, as well as on 
the fourth day. A blood sample was collected prior to cold ex- 
posure as described above, and an additional sample was col- 
lected after the 2-h cold exposure for measurement of cold-in- 
duced plasma ACTH and corticosterone concentrations. Food 
was unavailable for 1-2 h before as well as during this experi- 
ment. 
Materials and methods 
Animals. Lean heterozygous (Fa/fa) female rats (9-12 weeks 
old) of the Zucker strain, bred in our laboratories, were housed 
individually under conditions of controlled temperature 
(23 ~ and illumination (07.00-19.00 hours) and were provid- 
ed with standard laboratory chow (Provimi Lacta, Cossonay, 
Switzerland) and tap water. All experiments were approved 
by the ethical committee for animal experimentation of the 
Geneva University Faculty of Medicine, as well as by the Swiss 
Federal and Geneva Cantonal Veterinarian Offices. 
Placement of chronic jugular and intracerebroventricular 
(i. c.v.) cannulae. Under sodium pentobarbital anaesthesia 
(55 mg/kg i. p.; Siegfried, Zofingen, Switzerland), a catheter fil- 
led with 1.5:1 weight/volume polyvinylpyrrolidon (Merck, 
Darmstadt, Germany) in isotonic saline containing 250 IU/ml 
heparin (Liquemin; Roche Pharma, Reinach, Switzerland) 
and 10 000 IU/ml penicillin (Hoechst-Pharma, Zurich, Switzer- 
land) was placed in the right atrium via the jugular vein. A can- 
nula was placed in the right lateral cerebral ventricle as pre- 
viously described [22]. The jugular catheter was subcutaneous- 
ly tunnelled to be externalised and fixed to the skull next to the 
i.c.v, cannula using dental cement (Paladur; Heraeus Kulzer 
Insulin secretion induced by i. v. glucose injection. On day 4 or 5 
after minipump implantation, an i. v. bolus of glucose (300 mg/ 
kg) was injected via the jugular catheter between 10.00- 
11.30 hours. The catheter was rinsed with 0.5 ml of isotonic sa- 
line, and a 2 ml blood sample was collected between 1 and 
3rain post-injection into tubes containing 40~1 EDTA 
(24 mg/ml in isotonic saline, pH 7.4). Rats were immediately 
recompensed with 2 ml of donor blood. This large volume of 
blood was necessary for subsequent high performance liquid 
chromatography (HPLC) of plasma for the assay of insulin, 
proinsulin and conversion intermediates. 
Measurement of in vivo glucose utilisation during euglycaemic- 
hyperinsulinaemic clamps. After 6 days of i. c. v. infusion, pair- 
fed NPY-infused rats and a vehicle-infused control group 
were fasted for 6-8 h and prepared for euglycaemic-hyperinsu- 
linaemic clamps (using maximally effective plasma insulin con- 
centrations) associated with the labelled 2-deoxyglucose tech- 
nique to measure in vivo insulin-stimulated glucose utilisation 
index in individual tissues (diaphragm, quadriceps and gas- 
trocnemius, separated into red and white components, soleus, 
tibialis, extensor digitorum longus, inguinal white adipose tis- 
sue) [14]. Uptake and phosphorylation of 2-deoxyglucose by 
various tissues during the clamp was estimated as described 
[14] and expressed as a glucose utilisation index (ng/min x mg 
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tissue). Since the inguinal white adipose tissue weight of pair- 
fed NPY-infused rats was significantly greater than that of con- 
trol rats, the glucose utilisation index of this tissue was expres- 
sed in ng/min x ~tg DNA (total DNA content of fat pad was un- 
altered by NPY infusion). 
Measurement of hypothalamic corticotropin-releasing factor 
(CRF)-immunoreactivity. After 6 days of i.c.v, infusion, ani- 
mals were killed by decapitation between 11.00 and 
15.00 hours (3-7 h after removal of food from cages), the brain 
was removed, frozen on a cold table, and the hypothalamus 
was dissected and stored at -80 ~ until measurement of total 
CRF immunoreactivity and protein content as published else- 
where [23, 24]. Pancreases were also removed, snap frozen in 
liquid nitrogen, and stored at -80 ~ for later HPLC analysis 
of the different molecular forms of insulin. 
Reverse-phase HPLC of plasma and pancreatic extracts. In the 
ad libitum-fed group of NPY-infused rats and their controls, 
plasma (collected after i.v. glucose injection) and pancreases 
were analysed by HPLC to determine the relative proportions 
of insulin, proinsulin, and their conversion intermediates. Pan- 
creases were processed for HPLC as described by Schnetzler 
and colleagues [25]. Pancreatic extract (700 ~tl) or 1-5 ml of 
plasma (for controls, plasma from 6 rats was pooled due to 
low insulin concentrations) were purified on C18 Sep-Pak col- 
umns (Waters Associates, Milford, Mass., USA) as described 
[25]. We loaded 40-250 ~tl of sample (containing 360 ng immu- 
noreactive insulin for pancreatic extracts and 6-12 ng for plas- 
ma J~amples) onto a Lichrosphere 100-RP-18 column, 
4 • 250 mm (Merck, Darmstadt, Germany) connected to a Sys- 
tem Gold pump module 126 and detector module 166 (Beck- 
man Instruments, Fullerton, Calif., USA). Elution buffers 
were: A) 50 mmol/1 phosphoric acid, 20 mmol/1 triethylamine 
and 50 mmol/1 sodium perchlorate, pH 3.0) and B) 9 : 1 aceto- 
nitrile/water volume/volume. Insulin-like immunoreactive ma- 
terial was eluted at 1 ml/min and 38.5 % buffer B from 0- 
25 min, followed by a linear increase in the proportion of buf- 
fer B to 42.5 % between 25 and 95 min. We collected 1 ml frac- 
tions into glass tubes containing 100 ~tl 0.5 mol/1 borate/1% 
BSA, pH 9.2. Organic solvents in fractions were evaporated 
under vacuum, and lyophilised fractions were reconstituted in 
1 ml of 0.05 mol/1 phosphate buffer, pH 7.4, containing 1% 
BSA, and stored at -20~ until radioimmunoassay by the 
method of Herbert [11]. Peaks corresponding to mature insu- 
lin, proinsulin, and the conversion intermediates des 31,32- 
and des 64,65-split proinsulin were identified by comparison 
with previously characterised standards [26]. 
anaesthetised with sodium pentobarbital (55 mg/kg, i.p.), and 
the carotid artery was cannulated. After 30 min a bolus of glu- 
cose (300 mg/kg) was injected via the carotid catheter, which 
was rinsed with 0.2 ml of isotonic saline. At  0, 5, 10, 20, 30, 40, 
60 and 90 min after glucose injection 150 ixl blood samples 
were collected into heparinised tubes for subsequent determi- 
nation of plasma insulin and glucose concentrations. Integrat- 
ed areas under the resultant insulin response curves were cal- 
culated (after subtracting baseline values) between t = 0 and 
t = 60 min after glucose injection, when insulinaemia had re- 
turned to baseline values in all groups of rats. This integral is 
referred to as glucose-stimulated insulin output. 
Plasma hormone measurements. Plasma corticosterone con- 
centrations were measured by radioimmunoassay [11], and a 
kit from CIS Bio International (Gif-Sur-Yvette, France) was 
used for measurement of plasma ACTH. Insulinaemia was 
measured by radioimmunoassay [11] using guinea pig anti-rat 
insulin serum (Linco Research Inc., St. Louis, Mo. USA). Plas- 
ma glucose concentrations were determined using a kit from 
Boehringer (Mannheim, Germany). 
Statistical analysis. For the daily measurements of food intake, 
body weight, change in body weight, basal plasma ACTH, cor- 
ticosterone, insulin and glucose concentrations, differences in 
normal and vagotomised rats were assessed by one-way analy- 
sis of variance (ANOVA) with repeated measures followed by 
post-hoc Duncan's range tests. When two groups were found 
to be significantly different from each other, multiple Bonfer- 
roni comparisons were made to locate differences at each 
time point. Plasma ACTH and corticosterone concentrations 
before and after cold exposure (in ad libitum-fed NPY-infused 
and control rats) were compared by the Kruskal-Wallis non- 
parametric ANOVA test followed by Dunn's multiple com- 
parisons tests in order to detect differences betffeen the two 
groups of rats under basal or stimulated conditions, as well as 
differences within groups of rats induced by cold stress. Hypo- 
thalamic levels of CRF immunoreactivity in the three groups 
of rats were compared by one-way ANOVA followed by a Stu- 
dent-Newman-Keuls multiple comparisons test. Glucose-sti- 
mulated insulin output was compared between sham-vagoto- 
mised and vagotomised rats (i.c.v. infused with vehicle or 
NPY) by one-way ANOVA and Student-Newman Keuls mul- 
tiple comparisons. Differences between control and NPY-in- 
fused rats with respect to glucose utilisation index of various 
tissues and inguinal white adipose tissue weight were made by 
one-tailed Student's t-tests. For all analyses, values of p < 0.05 
were accepted as being statistically significant. 
Experiments involving vagotomiscd rats. Female Sprague- 
Dawley rats, bilaterally vagotomised (subdiaphragmatic) or 
sham-vagotomised at 8 weeks of age, were purchased from 
IFFA CREDO (L'Arbresle, France) and equipped with chron- 
ic jugular and i.c.v, cannulae as described above, using i.m. 
ketamin/xylazine anaesthesia (45 and 9 mg/kg, respectively, 
Parke-Davis and Bayer AG, Leverkusen, Switzerland). At 12 
weeks of age, rats were designated to one of four experimental 
groups: 1) sham-vagotomised + i. c.v. vehicle; 2) sham-vagoto- 
mised + i. c.v. NPY; 3) vagotomised + i. c. v. vehicle; 4) vagoto- 
mised + i. c.v. NPY. NPY or vehicle were i. c.v. infused as de- 
scribed above, and the food intake of all four groups was re- 
stricted to 22.0 g per day, the average amount consumed by 
sham-vagotomised and vagotomised rats prior to NPY infu- 
sion. Pellets were distributed as described for the pair-feeding 
protocol. Body weight, basal insulinaemia and glycaemia 
were measured daily as described for the other groups of rats. 
After 6 days of i.c.v, infusion, animals were fasted for 3-4 h, 
Results 
Effect o f  6-day i. c.v. N P Y  infusion on feeding and 
body weight gain. I .c .v .  N P Y  in fus ion  c a u s e d  a 
m a r k e d  inc rease  in ad  l ib i tum f o o d  i n t ake  w h i c h  was  
su s t a ined  fo r  the  6 days  o f  its infus ion .  F o o d  in t ake  
o n  day  6 was  52 _+ 7 g in N P Y - i n f u s e d  rats  c o m p a r e d  
to  19.1 g fo r  c o n t r o l s  (n = 6 -15 ,  p < 0.001). T h e  f o o d  
in t ake  o f  pa i r - f ed  N P Y  in fused  ra ts  was  r e s t r i c t ed  t o  
22.0 g p e r  d a y  as d e s c r i b e d  u n d e r  M a t e r i a l s  a n d  
M e t h o d s .  T h e  b o d y  we igh t  ga in  o f  ad  l i b i tum- fed  
N P Y - i n f u s e d  rats  was  s igni f icant ly  g r e a t e r  t h a n  tha t  
o f  c o n t r o l  ra ts  (27.4 + 4.3 g/6 days  vs 7.9 + 2.0 g/6 
days,  n = 6 -15 ,  p < 0.001) w h e r e a s  the  b o d y  we igh t  
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Fig.1. Basal plasma ACTH (upper panel) and corticosterone 
(lower panel) concentrations during i.c.v, infusion of NPY 
(15 btg/day) in normal rats allowed to eat ad libitum, or pair- 
fed with vehicle-infused controls ( @, NPY ad libitum-fed; A, 
NPY pair-fed; O, vehicle-infused controls). Plotted values are 
means+SEM of 6-15 rats per group. 4,p<0.01 and 
*** p < 0.001 vs corresponding value of vehicle-infused control 
rats. Ap < 0.05; AAp < 0.01 and AAAp < 0.001 vs correspond- 
ing value of pair-fed NPY-infused rats 
gain of pair-fed NPY-infused rats was no different 
from that of the control group. 
Effect of 6-day L c. v. NPYjnfusion on the hypothala- 
mo-pituitary adrenal (HPA) axis. In animals allowed 
to eat ad libitum, i. c. v. NPY infusion caused signifi- 
cant elevations in plasma ACTH levels compared to 
control values during the first 3 days of infusion 
(Fig. 1 upper panel). However, this effect of NPY was 
not sustained with continued infusion of the peptide; 
within 4--6 days of NPY infusion in ad libitum-fed 
rats, plasma A C T H  levels were not significantly differ- 
ent from those of control rats. In the same manner, 
plasma A C T H  levels of pair-fed NPY-infused rats ten- 
ded to be higher than those of control rats during the 
first day of NPY infusion, but were similar to control 
values during the remaining 5 days of peptide infusion. 
Compared to control values, plasma corticoster- 
one levels were significantly increased by i. c.v. NPY 
infusion in both ad libitum- and pair-fed rats (Fig. 1, 
lower panel). However, whereas Figure 1 shows that 
the hypercorticosteronaemia of ad libitum-fed NPY- 
infused rats remained present during the entire 6- 
day infusion period, that of pair-fed NPY-infused 
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Fig.2. Plasma ACTH (upper panel) and corticosterone (lower 
panel) concentrations under basal conditions and after 2 h at 
5 ~ measured after 2 days of i.c.v, infusion of NPY ( II, 
15 ~tg/day) or vehicle for control rats ( [] ). All animals were 
allowed to efftad libitum, but food was unavailable for 1-2 h 
prior to basal blood sampling and during cold exposure. Plot- 
ted values are means + SEM of 8-9 rats per group. ** p < 0.01 
and ***p < 0.001 vs corresponding value of vehicle-infused 
control rats. A p < 0.05 and AAA p < 0.001 vs basal value of 
the corresponding group 
rats was normalised from the third day of NPY infu- 
sion onwards. 
Figure 2 further shows that after 2 days of i.c.v. 
NPY infusion with ad libitum feeding, both basal 
plasma A C T H  and corticosterone concentrations 
were considerably greater than the corresponding va- 
lues of control rats. Plasma ACTH concentrations 
were further increased, in both control and NPY-in- 
fused rats, after 2 h of cold exposure (5 ~ relative 
to their respective basal (23~ values. The cold 
stress-induced plasma concentrations of A C T H  were 
much greater in NPY-infused rats than in control 
rats. The cold exposure also caused a marked increase 
in plasma corticosterone concentrations of control 
rats. In NPY-infused rats, the high plasma corticoster- 
one concentrations measured under basal conditions 
were not further increased by cold exposure, presum- 
ably because they had already reached maximum pla- 
teau values under basal conditions. 
On day 4, the same cold exposure in control rats 
still caused increases in plasma concentrations of 
A C T H  and corticosterone, while this failed to occur 
in ad libitum-fed NPY-infused rats (data not shown). 
After  6 days of i. c. v. NPY infusion, the quantity of 
corticotropin-releasing factor (CRF)-immunoreac- 
tivity in the hypothalamus was significantly reduced 
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Fig.& Basal plasma insulin concentrations during i.c.v, infu- 
sion of NPY (15 ~tg/day) in normal rats allowed to eat ad libi- 
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tum-fed; A, NPY pair-fed; O, vehicle-infused controls). Plot- 
ted values are means + SEM of 6-15 rats per group. * p < 0.05; 
9 * p < 0.01 and ***p < 0.001 vs corresponding value of vehi- 
cle-infused control rats 
relative to control values (Fig. 3). This decrease in hy- 
pothalamic CRF content was observed in both pair- 
fed and in ad libitum-fed NPY-infused rats, and the 
difference between the two groups of NPY-infused 
rats was not significant. There was no difference be- 
tween the three groups of rats shown in Figure 3 
with respect to total protein content per hypothala- 
mus (data not shown). 
Effect o f  6-day i. c. v. N P Y  infusion on insulin output. 
Chronic i.c.v. NPY infusion resulted in significant 
increases in basal insulinaemia in both ad libitum-fed 
rats and in rats that were pair-fed with vehicle-infused 
controls (Fig. 4). This NPY-induced hyperinsulinae- 
mia was present after 1 day of i.c.v. NPY infusion 
and was sustained during the entire 6 days of NPY in- 
fusion. 
In addition to basal hyperinsulinaemia, insulin se- 
cretion in response to i.v. glucose injection (300 rag/ 
kg) was also increased in rats infused with NPY (ad 
libitum- or pair-fed) compared with vehicle-infused 
control rats (data not shown). This is despite the fact 
that plasma glucose concentrations were increased 
to identical values in all groups of rats by the i.v. glu- 
cose bolus. 
The above-mentioned levels of basal and stimulat- 
ed insulinaemia represent measures of total insulin- 
like immunoreactivity in plasma, which includes not 
only mature insulin but also proinsulin, and the con- 
version intermediates des 64,65- and des 31,32-split 
proinsulin [27]. These intermediates are formed by 
endoproteolytic cleavage at the A-chain/C-peptide 
and the B-chain/C-peptide junctions of proinsulin, re- 
spectively, followed by enzymatic trimming of resi- 
dual C-terminal basic amino acids [27]. To determine 
whether  the composition of total insulin-like immu- 
noreactivity in plasma after i.v. glucose stimulation 
was altered by i. c. v. NPY infusion, a plasma sample 
collected 1-3 min after a bolus glucose injection was 
fractionated by HPLC prior to radioimmunoassay. 
In ad libitum-fed NPY-infused rats as in control rats, 
mature insulin contributed to over 90 % ef the total 
plasma insulin-like immunoreactivity, the remaining 
being made up of proinsulin and conversion inter- 
mediates (data not shown). Six days of i. c.v. NPY in- 
fusion in ad libitum-fed rats had no effect on either 
the wet weight of the pancreas, or on the total quanti- 
ty of insulin-like immunoreactivity in the pancreas 
(Table 1). The composition of total pancreatic insu- 
lin-like immunoreactivity was no different in NPY- 
treated rats compared to control rats, with over 94 % 
of the pancreatic insulin-like immunoreactivity being 
due to mature insulin in both cases, intact proinsulin, 
des 64,65- and des 31,32-split proinsulin making up 
the remaining 6 % (Table 1). 
Metabolic consequences o f  6-day i. c. v. N P Y  infusion 
with pair-feeding regime. As shown in Figure 5, the in- 
sulin-stimulated glucose utilisation index of muscles 
measured during euglycaemic-hyperinsulinaemic 
clamps was decreased after 6 days of i. c.v. NPY infu- 
sion with pair-feeding to control rats, indicating mus- 
cle insulin resistance. NPY infusion tended to also 
cause a decrease in insulin-stimulated glucose utilisa- 
tion index in other muscles studied and not shown in 
the figure, although the intergroup difference was 
not statistically significant. In contrast, the glucose 
utilisation index of inguinal white adipose tissue was 
significantly increased after 6 days of central NPY 
administration with pair-feeding (Fig.5). Inguinal 
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Table 1. Effect of 6-day i.c.v. NPY infusion (15 ~tg/day) on 
pancreas weight, total insulin content, and relative proportions 
of insulin biosynthetic products in the pancreas 
Control i.c.zNPY 
0.68• 0.74• Wet weight of pancreas (g) 
Total insulin-like immunoreactivity 
per pancreas (~tg) 
% Mature insulin 
% des 31,32-split proinsulin 
% des 64,65-split proinsulin 
% Proinsulin 
24.7• 32.1• 
95.2• 94.1• 
2.5• 3.1• 
0.7• 0.8• 
1.6• 2.0• 
All animals were allowed to eat ad libitum during the i. c. v. in- 
fusion. Values are means _+ SEM of 3-7 rats per group. There 
was no significant difference between control and NPY-infused 
rats 
white adipose  tissue weight  was significantly grea ter  
in pair-fed NPY-infused rats than  in control  rats 
(1.4 + 0.2 g vs 1.0 + 0.1 g, n = 5-6,  p < 0.05). When  ad 
l ibi tum-fed dur ing 6-day i. c. v. N P Y  infusion, this in- 
crease in inguinal  white adipose  tissue weight was 
more  p r o n o u n c e d  (2.4 + 0.2 g vs 1.1 + 0.2 g in vehi- 
cle-infused controls,  n = 5-7,  p < 0.005). 
Fig.5. Glucose utilisation index of various muscles (Diaph, 
diaphragm; RQ, red quadriceps; RG, red gastrocnemius; Sol, 
soleus; EDL, extensor digitorum longus) and of inguinal white 
adipose tissue (WATi), measured during euglycaemic-hyperin- 
sulinaemic clamps after 6 days of i. c. v. infusion of NPY (15 ~tg/ 
day) in normal rats that were pair-fed with vehicle-infused con- 
trols ([], NPY pair-fed; I-1, vehicle-infused controls). Plotted 
values are means _+ SEM of 5-6 rats per group. * p < 0.05 vs 
corresponding value of control rats 
Impact o f  vagotomy on i.c.v. NPY-induced insulin 
output. For  these  experiments ,  the  food  intake of  all 
four  groups  of  rats ( sham-vagotomised  and vagoto-  
mised, i.c.v, infused with vehicle or  N P Y )  was re- 
str icted to tha t  of  vehicle- infused rats (22.0 g per  
day).  Such pai r  feeding was impor t an t  because  sub- 
strate- and vagus ne rve -med ia t ed  insulin ou tpu t  are 
inf luenced by  substra te  availabili ty [28]. The re  was 
no  significant d i f ference  be tween  the  four  groups of  
rats with respec t  to absolute  b o d y  weight,  body  
weight gain, or  basal g lycaemia dur ing the 6-day infu- 
sion per iod.  
The  m e a n  basal insul inaemia m e a s u r e d  during 6 
days of  i. c. v. infusion of  vehicle or  N P Y  in sham-va- 
go tomised  rats or  rats with bi lateral  subdiaphragmat-  
ic vago tomy  are  shown in Figure 6. I. c.v. N P Y  infu- 
sion p roduced  a significant increase in the basal insu- 
l inaemia of  sham-vagotomised  rats, but  had  no effect  
on  the basal insul inaemia  of  vago tomised  rats. As fur- 
ther  shown by Figure 6, i. v. g lucose-s t imulated insulin 
ou tpu t  was cons iderably  increased by  i. c. v. N P Y  infu- 
sion in sham-vagotomised  rats, bu t  was unaf fec ted  by 
i. c. v. N P Y  in vago tomised  animals. No te  that  the gly- 
caemic response  in the 90 min af te r  i. v. glucose injec- 
t ion was ident ical  in the four  groups  of  rats shown in 
Figure 6. 
Fig.6. Basal plasma insulin concentrations (upper panel) and 
insulin output after an i.v. bolus injection of 300 mg/kg glucose 
(lower panel) during i.c.v, infusion of NPY (15 vg/day) in 
sham-vagotomised or vagotomised rats compared to vehicle- 
infused sham or vagotomised rats (I3, vehicle-infused sham va- 
gotomised; [ ]  NPY sham-vagotomised; vehicle-infused va- 
gotomised; NPY vagotomised). Food intake of all animals 
was restricted to 22.0 g/day (pair-feeding). Plotted values are 
means + SEM of 4-6 rats per group. * p < 0.05 vs vehicle-in- 
fused sham-vagotomised rats 
Discussion 
The  aim of  this s tudy was to charac ter ise  the longitu- 
dinal changes  in activity of  the hypotha lamo-pi tu i -  
ta ry-adrenal  (HPA)  axis and in insulin secre t ion 
dur ing 6 days of  in t race rebroven t r i cu la r  (i. c.v.) infu- 
sion of  neu ropep t ide  Y (NPY)  in normal  rats, and to 
de t e rmine  the impact  of  subdiaphragmat ic  v a g o t o m y  
on  NPY- induced  insulin secret ion.  
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Past research has shown that acute injection of 
NPY into the cerebral ventricles or into the hypotha- 
lamic paraventricular nucleus (PVN) stimulates the 
HPA axis of several species [3]. Such NPY-induced 
changes include increases in corticotropin-releasing 
factor (CRF) mRNA levels and immunoreactivity in 
the PVN [29, 30], and increases in plasma adrenocor- 
ticotropic hormone (ACTH) and corticosterone con- 
centrations [3]. In vitro, NPY stimulates CRF secre- 
tion from hypothalamic fragments [3], and it may 
also increase the sensitivity of cultured pituitary cells 
to CRF-induced secretion of ACTH [3], although 
this has not been a unanimous finding [31, 32]. There 
is some evidence that endogenous NPY may influ- 
ence the activity of the HPA axis in vivo, since NPY- 
ergic nerve terminals have been shown to make con- 
tact with CRF-synthesising perikaryon of the PVN 
[3], and since i. c. v. infusion of anti-NPY serum elimi- 
nated the stress-induced increase in plasma ACTH 
concentrations in dogs [3]. 
In the present study it was shown that NPY stimu- 
lated the basal and stress-induced activity of the 
HPA axis during the first 2 days of its i. c.v. infusion. 
Although feeding is known to increase plasma 
ACTH and corticosterone concentrations [33], this 
effeet of i. c.v. NPY infusion was not simply due to 
the associated increase in food intake (hyperphagia), 
since it was observed, albeit to a lesser extent, even 
when NPY-induced hyperphagia was prevented by a 
pair-feeding regime. However, after 4 to 6 days of 
continuous i.c.v. NPY administration, basal plasma 
concentrations of ACTH and corticosterone were 
normalised or tending towards normal control values, 
there was no change in their plasma concentrations in 
response to stress, and the hypothalamic content of 
CRF-immunoreactivity was reduced relative to con- 
trol values. These findings suggest that chronic cen- 
tral NPY administration ultimately inhibits the activ- 
ity of the HPA axis. One possible explanation for 
this is that the NPY Y1 receptor, which is thought to 
be responsible for the effects of N P u  on the HPA 
axis [34], may be down-regulated in the face of 6-day 
exposure to its agonist, while such down- regulation 
would not occur for the NPY Y5 receptor, responsible 
for the effect of NPY on food intake [35]. An addi- 
tional possibility is that the elevated plasma concen- 
trations of corticosterone during the first few days of 
i. c.v. NPY infusion could inhibit the activity of the 
HPA axis by feedback inhibition of CRF and ACTH 
secretion [36, 37]. The latter scenario is presently fa- 
voured since it would explain not only the normalisa- 
tion of basal plasma ACTH and corticosterone levels 
observed after several days of central NPY adminis- 
tration, but also the total lack of stress-induced secre- 
tion of these hormones at this time, as well as the de- 
crease in hypothalamic CRF-immunoreactivity [37]. 
These data suggest that the hypercorticism of geneti- 
cally obese rodents [19] may not be caused by the 
associated increase in hypothalamic NPY-ergic activ- 
ity, and other routes, such as increases in arginine va- 
sopressin regulation of the HPA axis [38], need to be 
investigated. 
Although the effects of acute central NPY injec- 
tion on insulin secretion are small or absent, as stu- 
died and reviewed [21], a sustained increase in basal 
insulinaemia was apparent during chronic (6 days) 
central NPY infusion in normal rats. This effect of 
NPY, which is in agreement with reports of others 
[10, 11], was manifest after just 1 day of its i. c. v. infu- 
sion. It was present both in animals that were ad libi- 
turn-fed during central NPY infusion, as well as in 
those that were pair-fed along with vehicle-infused 
control rats, demonstrating that this hyperinsulinae- 
mia was not simply a consequence of NPY-induced 
hyperphagia. The basal hyperinsulinaemia of rats in- 
fused with NPY was accompanied by a hypersecre- 
tion of insulin in response to stimuli such as i.v. injec- 
tion of glucose as presently shown, or ingestion of a 
meal [12]. 
In patients with non-insulin-dependent diabetes 
mellitus (NIDDM), increases in the absolute or rela- 
tive amounts of proinsulin in the plasma (compared 
to plasma concentrations of mature insulin) are en- 
countered [39-41]. It is hypothesised that the chronic 
stimulation of insulin secretion in NIDDM patients 
leads to an increased output of immature insulin se- 
cretory granules in which the ratio of proinsulin and 
conversion intermediates to insulin is higher than 
that of mature granules [27, 40, 41]. It was therefore 
of interest to study proinsulin secretion in an animal 
model presenting sustained hyperstimulation of insu- 
lin secretion. In the present study, rats i. c.v. infused 
with NPY for 6 days, although hyperinsulinaemic, 
show no evidence of perturbations in the molecular 
forms of secreted insulin and related peptides, or in 
the relative proportions of these molecules in the 
pancreas. It must therefore be concluded that in- 
creased insulin turnover in the beta cell per se, as in 
the present model, does not necessarily lead to any 
perturbation in proinsulin conversion. 
This work shows for the first time, using pair-feed- 
ing conditions to completely abolish NPY-induced  
hyperphagia, that 6 days of central NPY infusion re- 
sulted in a state of insulin resistance in muscles (as in- 
dicated by reduced 2-deoxyglucose uptake and phos- 
phorylation relative to control rats) and a hyperre- 
sponsiveness of such insulin-induced glucose uptake 
and phosphorylation in white adipose tissue. Al- 
though such changes in peripheral glucose metabo- 
lism have been observed in freely feeding, hyperpha- 
gic i. c.v. NPY-infused rats [12-14], the present data 
show that even in the absence of an increase in sub- 
strate supply, central NPY infusion placed the ani- 
mals in a "thrifty" phenotype channelling glucose car- 
bon away from utilisation and into lipid accretion 
pathways. This is reflected by the increases in inguinal 
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white adipose tissue weight of both  pair-fed and ad li- 
bi tum-fed NPY-infused rats compared  to controls. 
These metabol ic  effects of chronic i. c.v. NPY infu- 
sion may  be a consequence of the t ransient  hypercor- 
t icosteronaemia [15] and especially the sustained hy- 
perinsul inaemia [16] presently repor ted  under  both  
ad libitum- and pair-feeding conditions. 
Finally, the present  investigation demonst ra tes  
that  i. c.v. NPY infusion increases basal and  stimulat- 
ed insulinaemia via activation of  the vagus nerve, 
since bilateral subdiaphragmatic  vago tomy preven- 
ted such NPY-induced increases in insulinaemia.  Si- 
milarly, o ther  effects of central  NPY injection on the 
gastrointestinal  tract  (such as increases i n  gastric 
acid, bile and pepsin secretion) are med ia t ed  by vagal 
cholinergic pa thways  [42]. Recent  work f rom this la- 
bora tory  [14] has shown that  adrena lec tomy is able 
to prevent  hyper insul inaemia  during chronic central  
NPY infusion in rats. Other  investigators have shown 
that  the insulin hypersecret ion of genetically obese 
fa/fa rats, which present  spontaneously  e levated hy- 
pothalamic NPY expression [6], can be abolished by 
adrenalectomy, res tored by i. c.v. or per ipheral  gluco- 
corticoid replacement ,  and subsequent ly  blocked by 
the cholinergic antagonist  atropine [43, 44]. It was 
concluded that  glucocorticoids play a permissive role 
in the parasympathet ica l ly  media ted  hyperinsulinae- 
mia of fa/fa rats. These data  collectively suggest that  
high NPY levels in the hypotha lami  of genetically 
obese rodents  s t imulate insulin secret ion by activat- 
ing parasympathet ic  efferents to the pancreas, the 
preganglionic neurones  of which are mainly  located 
in the dorsal m o t o r  nucleus of the vagus [45], and 
that  this effect of  NPY is dependen t  on circulating 
glucocorticoids, probably acting within the central  
nervous system. 
In summary,  chronic central  NPY infusion resulted 
in t ransient  act ivat ion of the HPA axis fol lowed by an 
eventual  inhibit ion of this axis, and a sustained, vagal- 
ly media ted  increase in basal and substrate- induced 
insulinaemia. Considering the key role of  insulin in 
metabol ic  homeostas is  [16], fur ther  work  a imed at 
unders tanding how NPY activates vagal efferents  to 
the pancreas, and the role of glucocorticoids in this 
process, could contr ibute  to our  knowledge  of the me- 
tabolic defects associated with obesity syndromes in 
which NPY expression in the hypotha lamus  is chroni- 
cally elevated. 
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